Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

Leukemia

Volumn 28, Issue 6, 2014, Pages 1299-1307

  Ladetto, M ^a   Bruggemann M ^b   Monitillo, L ^a   Ferrero, S ^a   Pepin, F ^c   Drandi, D ^a   Barbero, D ^a   Palumbo, A ^a   Passera, R ^a   Boccadoro, M ^a   Ritgen, M ^b   Gokbuget N ^d   Zheng, J ^c   Carlton, V ^c   Trautmann, H ^b   Faham, M ^c   Pott, C ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Sequenta Inc   (United States)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

acute lymphoblastic leukemia; immunoglobulin (IGH) gene rearrangement; mantle cell lymphoma; multiple myeloma; T cell receptor gene rearrangement (TCR)

Indexed keywords

DNA; OLIGONUCLEOTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CLONAL VARIATION; CLONING; CLONOTYPE IDENTIFICATION; CLONOTYPE IDENTITY; DNA EXTRACTION; FEASIBILITY STUDY; GENE SEQUENCE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ADULT; BINDING SITE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLONAL EVOLUTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; GENE REARRANGEMENT; HIGH THROUGHPUT SEQUENCING; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION;

DNA, NEOPLASM; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA, MANTLE-CELL; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84902075123     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.375     Document Type: Article

References (40)

1. Pott C. Minimal residual disease detection in mantle cell lymphoma: Technical aspects and clinical relevance. Semin Hematol 2011; 48: 172-184.
2. Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: Impact on therapeutic paradigms. Hematol Oncol 2011; 29: 167-176.
3. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: Monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012; 39: 47-57.
4. Brüggemann M, Raff T, l Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470-4481.
5. Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012; 19: 313-318.
6. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
7. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115: 4657-4663.
8. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116-1123. (Pubitemid 43156313)
9. Raff T, Kaiser M, Gökbuget N, Lüschen S, Ritgen M, Trautmann H et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 2007; 109: 910-915.
10. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-4162.
11. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083-1098.
12. Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R et al. Adult patients with acute lymphoblastic leukemiaand molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868-1876.
13. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, Van Der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-Time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782. (Pubitemid 351552626)
14. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study. Blood 2010; 115: 3215-3223.
15. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO/IIL trial comparing in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004-4013.
16. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
17. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P et al. Long-Term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057-1065. (Pubitemid 47224617)
18. Paiva B, Gutiérrez NC, Rosiñol L, Vidriales MB, Montalban MA, Martinez-Lopez J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691.
19. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988.
20. Pott C, Brüggemann M, Ritgen M, Van Der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-Time quantitative. Methods Mol Biol Vol. 971. Humana press: Hertfordshire, UK, 2013, pp 175-200.
21. Van Der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-Time quantitative PCR data. Leukemia 2007; 21: 604-611. (Pubitemid 46444541)
22. Szczepański T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415-1423.
23. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 2012; 120: 4407-4417.
24. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.
25. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, Van Der Burg M, van Dongen JJM. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99: 2315-2323. (Pubitemid 34525415)
26. Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M et al. Minimal residual disease quantification using consensus primers and high-Throughput IGH sequencing predicts post-Transplant relapse in chronic lymphocytic leukemia. Leukemia 2013; 27: 1659-1665.
27. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173-5180.
28. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
29. Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241-253.
30. Brüggemann M, Droese J, Bolz I, Lüth P, Pott C, von Neuhoff N et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-Time quantitative PCR. Leukemia 2000; 14: 1419-1425.
31. Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E et al. Minimal residual disease detection in mantle cell lymphoma: Methods and significance of fourcolor flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008; 93: 551-559.
32. Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998; 12: 1630-1637. (Pubitemid 28470450)
33. Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P et al. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-Time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365-1372. (Pubitemid 41503652)
34. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-535.
35. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365-4370.
36. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-Term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
37. Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D et al. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica 2012; 97: 849-853.
38. Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011; 118: 3088-3095.
39. Hadzidimitriou A, Stamatopoulos K, Belessi C, Lalayianni C, Stavroyianni N, Smilevska T et al. Immunoglobulin genes in multiple myeloma: Expressedand non-expressed repertoires, heavy and light chainpairings and somatic mutation patterns in a series of 101 cases. Haematologica 2006; 91: 781-787. (Pubitemid 44014544)
40. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-Term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460-1468. (Pubitemid 41103629)